Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299819 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00299819 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 45 participants.
The verdict
NCT00299819, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.
Interventions
- BIOLOGICAL MEDI 545
- BIOLOGICAL MEDI-545
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299819
The ClinicalTrials.gov registry entry for NCT00299819 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI 545 is the first listed.
NCT00299819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299819 about?
NCT00299819 is a clinical study titled "Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)". The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of ...
What is the current status of trial NCT00299819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2006-03. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00299819?
The interventions under investigation include: MEDI 545 (BIOLOGICAL), MEDI-545 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00299819?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.